Please assess the completion status of the following clinical trial:

Trial Title: Vaccine Therapy in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed melanoma meeting the following criteria:~  * Unresectable recurrent disease~ * Stage III or IV disease~ * Cutaneous, ocular, or mucosal melanoma~* Measurable disease as defined by the RECIST criteria~* HLA-A2 positive~* Prior brain metastases allowed provided adequate surgical or radiologic treatment for brain disease~PATIENT CHARACTERISTICS:~* ECOG performance status 0 or 1~* WBC ≥ 3,000/mm³~* Lymphocytes ≥ 1,000/mm³~* Platelet count ≥ 100,000/mm³~* Creatinine ≤ 1.5 times upper limit of normal (ULN)~* Bilirubin ≤ 1.5 times ULN~* AST and ALT ≤ 2.5 times ULN~* Lactic dehydrogenase ≤ 2.0 times ULN~* aPTT \< 40 seconds~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception for ≥ 1 week before, during, and for ≥ 2 weeks after completion of study therapy~* No conditions of immunosuppression~* Negative titers for antinuclear antibody (≤ 1/80) and antidouble stranded DNA (≤ 1/10)~* No serious illnesses including, but not limited to, any of the following:~  * Bleeding disorders~ * Autoimmune diseases~ * Severe obstructive or restrictive pulmonary diseases~ * Active systemic infections~ * Inflammatory bowel disorders~* No serious cardiovascular disease including, but not limited to, any of the following:~  * Uncontrolled congestive heart failure~ * Hypertension~ * Cardiac ischemia~ * Myocardial infarction,~ * Severe cardiac arrhythmia~* HIV1 and 2 negative~* HTLV-1 negative~* Hepatitis B and C negative~* No significant psychiatric disease, medical intervention, or other condition that, in the opinion of the principal investigator, would limit study compliance~* No active infection within the past week, including unexplained fever (temperature \> 38.1°C)~PRIOR CONCURRENT THERAPY:~* Fully recovered from prior major surgery~* More than 4 weeks since prior chemotherapy (6 weeks for mitomycin C or nitrosoureas), hormonal therapy, radiotherapy, or biological therapy~* More than 1 week since prior antibiotics~* More than 28 days since prior investigational agent~* No prior vaccination with MART-1 (26-35, 27L), gp100 (209-217, 210M), and tyrosinase (368-376, 370D) peptides alone or in combination~  * Patients with history of vaccination with peptides other than MART-1 (26-35, 27L), gp100 (209-217, 210M), and tyrosinase (368-376, 370D) peptides allowed~* More than 4 weeks since prior and no concurrent systemic immunosuppressive therapy, including steroids~  * Patients on maintenance steroids given at physiologic doses because of adrenal insufficiency are eligible~* More than 2 weeks since prior and no concurrent treatment with systemic steroids, including oral steroids, continuous use of topical steroid creams or ointments, or any inhaled steroids~* No concurrent anticoagulants, except to keep an indwelling line patent~* No other concurrent anticancer therapy, including chemotherapy, immunotherapy, radiotherapy, experimental programs, and/or surgery

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Peptide Vaccine + GM-CSF + Pfizer 3512676 in-ISA Oil (Type: EXPERIMENTAL): The water-in-oil emulsion will consist of peptide (100 mcg/0.1 mL), GM-CSF (80 mcg/0.16 mL using lyophilized 500 mcg/vial reconstituted with 1 mL of sterile water), Pfizer PF3512676 (0.6 mg/0.04 mL using 15mg/mL vial) and 0.20 mLl of sterile saline.~Vaccination will be given subcutaneously rotating truncal sites in the vicinity of the four nodal drainage groups of the four extremities, on days 1 and 15 of each cycle (1 cycle = 28 days) for a maximum of 13 cycles (1 year).

Based on this trial design, predict the completion outcome and termination type (if applicable).